BTZ043

• Description:

  BTZ043 is an inhibitor of decaprenyl-phosphoribose-epimerase (DprE1), with MICs of of 2.3 nM and 9.2 nM for M. tuberculosis H37Rv and Mycobacterium smegmatis, respectively.

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H319, H335

• Target:

  Antibiotic; Bacterial

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/BTZ043.html

• Concentration:

  10mM

• Purity:

  99.51

• Solubility:

  DMSO : 13.3 mg/mL (ultrasonic; warming)

• Smiles:

  O=C1N=C(N(CC2)CCC32OC[C@H](C)O3)SC4=C([N+]([O-])=O)C=C(C(F)(F)F)C=C14

• Molecular Formula:

  C17H16F3N3O5S

• Molecular Weight:

  431.39

• Precautions:

  H315, H319, H335

• References & Citations:

  [1]Vadim Makarov et al. The 8-Pyrrole-Benzothiazinones Are Noncovalent Inhibitors of DprE1 fromMycobacterium tuberculosis. Antimicrob Agents Chemother, 2015 Aug, 59 (8) : 4446-4452.|[2]Makarov V, et al. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science. 2009 May 8;324 (5928) :801-4.|[3]Norma Alejandra González-Martínez et al. In Vivo Activity of the Benzothiazinones PBTZ169 and BTZ043 against Nocardia brasiliensis. PLoS Negl Trop Dis, 2015 Oct, 9 (10) : e0004022.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• CAS Number:

  [1161233-85-7]